StreetInsider.com News Articles

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit

Mon, 14 Sep 2026 23:00:00 -0400

● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16

● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses

● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies

VANCOUVER, BC / ACCESS Newswire / September 14, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company developing

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 14, 2026) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe" or the "Company") is pleased to announce its participation in the upcoming 3^rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Dr. David Kideckel, Ph.D., MBA, Chief Financial Officer of Lobe Sciences, will participate as a Featured Company and will hold one-on-one meetings with interested investors and capital markets professionals.

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

Mon, 14 Sep 2026 08:00:00 -0400

"This is a valuable opportunity to introduce Lobe Sciences to Canadian and U.S. investors. We are advancing innovative therapies for neurological and

Lobe Sciences closes $2.16M private placement for S-100 drug program

Mon, 31 Aug 2026 19:00:20 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, Frankfurt: LOBE.F) has closed a two-tranche non-brokered private placement, issuing a total of 25,411,762 common shares at $0.085 per share for gross proceeds of $2,160,000, according to a company statement.

The first tranche, closed Aug. 19, 2026, raised $2,100,000 through the issuance of 24,705,880 shares. A second tranche, driven by additional investor demand, raised $60,000 through 705,882 shares.

The company said proceeds will be used for working capital, general corporate purposes, and to advance its S-100 drug candidate for the treatment of sickle cell disease. A portion will be directed to its subsidiary, Applied Lipid

Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement

Mon, 31 Aug 2026 19:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESS Newswire / August 31, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce closing of the second tranche of its previously announced non-brokered private placement offering of common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share (the "Private Placement").

The Company closed the first tranche of the Private Placement

Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement

Mon, 31 Aug 2026 19:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

The Company closed the first tranche of the Private Placement

Lobe Sciences upsizes private placement to $2.16M

Fri, 28 Aug 2026 19:00:16 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, Frankfurt: LOBE) has announced an upsize to its non-brokered private placement of common shares at $0.085 per share.

The company closed the first tranche of the offering on August 19, 2026, issuing 24,705,880 shares for gross proceeds of $2,100,000. A second tranche of 705,882 shares is planned, targeting approximately $60,000 in additional gross proceeds. If the second tranche closes, the total offering will amount to 25,411,762 shares for aggregate gross proceeds of $2,160,000.

According to a press release, the company intends to use the proceeds for working capital, general corporate purposes, and to advance its

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement

Fri, 28 Aug 2026 19:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce an upsize to its previously announced non-brokered private placement offering of common shares in the capital of the Company ("CommonShares") at a price of $0.085 per Common Share (the "Private Placement").

The Company closed the first tranche of the Private Placement on August 19, 2026

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement

Fri, 28 Aug 2026 19:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

The Company closed the first tranche of the Private Placement on August 19, 2026

Lobe Sciences Expands Leadership Team with New CFO Appointment

Fri, 28 Aug 2026 08:00:00 -0400

Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experience
Current CFO, Mirza Rahimani, transitions to Vice President of Finance, providing continuity across financial reporting and operations
Appointment strengthens Lobe's leadership team as the Company advances L-130, its differentiated conjugated psilocin therapeutic being developed at sub-hallucinogenic doses for chronic cluster headache

VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing differentiated therapeutics for serious conditions with

Lobe Sciences Expands Leadership Team with New CFO Appointment

Fri, 28 Aug 2026 08:00:00 -0400

Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experience
Current CFO, Mirza Rahimani, transitions to Vice President of Finance, providing continuity across financial reporting and operations
Appointment strengthens Lobe's leadership team as the Company advances L-130, its differentiated conjugated psilocin therapeutic being developed at sub-hallucinogenic doses for chronic cluster headache

Lobe Sciences closes $2.1M private placement for sickle cell program

Thu, 20 Aug 2026 08:01:10 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, Frankfurt: LOBE) has closed a non-brokered private placement, issuing 24,705,880 common shares at $0.085 per share for gross proceeds of approximately $2,100,000, according to a company statement.

The Vancouver-based clinical-stage biopharmaceutical company said proceeds will be used for working capital and general corporate purposes, with a portion directed to its wholly owned subsidiary, Applied Lipid Technologies, Inc., to advance its S-100 drug candidate for sickle cell disease toward human clinical trials. The company said it has already procured the active pharmaceutical ingredient required for those studies.

All securities issued under the placement are subject to

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement

Thu, 20 Aug 2026 08:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce the closing of its previously announced non-brokered private placement offering of 24,705,880 common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share, for aggregate gross proceeds of approximately $2,100,000 (the "Private Placement").

The Company intends to use

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement

Thu, 20 Aug 2026 08:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

The Company intends to use

Lobe Sciences Reports Third Quarter 2026 Financial Results

Tue, 18 Aug 2026 08:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / August 18, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, today announced its unaudited interim financial results for the third quarter of fiscal 2026 ended May 31, 2026 ("Q3 2026").

During the quarter, the Company continued to advance its development pipeline while maintaining a disciplined approach to capital allocation. Management believes the progress achieved in Q3 2026 reflects continued execution on its strategic priorities and reinforces the Company's focus on building long-term shareholder

Lobe Sciences Reports Third Quarter 2026 Financial Results

Tue, 18 Aug 2026 08:00:00 -0400

Lobe Sciences plans $2.1M private placement to fund S-100 development

Wed, 12 Aug 2026 08:46:11 -0400

Lobe Sciences Ltd. (CSE: LOBE, OTCQB: LOBEF, FSE: LOBE.F) announced a non-brokered private placement of 24,705,880 common shares at $0.085 per share, for aggregate gross proceeds of approximately $2,100,000.

According to a press release, the company intends to use the net proceeds to fund cash reserves, advance clinical development of the S-100 molecule being developed by its subsidiary Applied Lipid Technologies Inc., and for working capital and general corporate purposes.

S-100 is Applied Lipid Technologies' lead asset, currently targeting sickle cell disease as its initial indication. The company has stated it intends to evaluate S-100's potential eligibility for orphan-drug designation and for

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

Wed, 12 Aug 2026 08:45:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, is pleased to announce a non-brokered private placement offering of 24,705,880 common shares in the capital of the Company ("Common Shares") at a price of $0.085 per Common Share, for aggregate gross proceeds of approximately $2,100,000 (the "Private Placement").

The Company intends to use the net proceeds of the Private

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

Wed, 12 Aug 2026 08:45:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

The Company intends to use the net proceeds of the Private

Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders

Wed, 05 Aug 2026 08:00:00 -0400

Shareholders Approve All Matters Presented at Meeting, Including New Long-Term Incentive Plan and Amendment to Constating Documents

VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FSE:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing therapeutic development programs through focused subsidiary companies, today announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on July 30, 2026.

A total of 152,807,032 common shares were represented at the Meeting, representing approximately 49.6% of the Company's issued and outstanding common shares as of the June